The 27th China Beijing International High-Tech Expo (referred to as the “Beijing CHITEC”) recently concluded successfully. Under the theme “Technology Empowering a Creative Future,” this year’s event featured six thematic exhibition zones: Information Technology, Intelligent Manufacturing, Pharmaceuticals & Healthcare, Green & Carbon Neutrality, Digital Economy, and Regional Innovation. More than 800 enterprises and institutions from both China and abroad participated in the exhibition.
As a national platform for global exchange and cooperation in science and technology innovation, the forum focused on “New Quality Productive Forces and Global Technological Cooperation.” It explored cutting-edge technology and industry development trends and facilitated discussion on how innovation can cultivate new quality productive forces, offering new ideas for global innovation and development.
AccuMedical Beijing Ltd., a prominent representative in the field of neurointervention, showcased its core product — Lattice Flow Diverter — as well as the newly upgraded Lattice NEXT Flow Diverter featuring a “no extended tip guidewire” design for 2025. The exhibition fully demonstrated the innovation strength and clinical achievements of Chinese enterprises in neurointervention, attracting extensive attention from domestic and international science and technology enthusiasts, professionals, and investors.
Flagship Products Take Center Stage, Innovation Recognized
At the Shunyi Exhibition Zone, AccuMedical’s booth became a major highlight. The Lattice Flow Diverter, known for its precise implantation, brings new hope to patients with intracranial aneurysms. Made of cobalt-chromium alloy, this product is equipped with the world’s first mechanical balloon delivery system and MIROR surface modification technology — groundbreaking innovations that fill several domestic gaps. It significantly reduces surgical complexity, shortens procedure time, and improves patient recovery and safety, ushering in the “automatic gear” era of aneurysm treatment.
Currently, the Lattice has been adopted in over 500 hospitals across China. It has earned widespread recognition from clinicians and is gradually expanding to remote and county-level hospitals, enabling more patients in underserved areas to benefit from advanced treatment.
Technology Empowers Healthcare: Delivering “Chinese Wisdom” to the World
During the expo, AccuMedical provided a comprehensive overview of its core technologies and clinical achievements, offering a uniquely “Chinese solution” for intracranial aneurysm treatment. Technology-driven innovation has always been the company’s core competitiveness. So far, nine of its products — including Lattice and Lattice NEXT — have been approved by the NMPA, with 132 patent applications filed, 73 of which have already been granted. The Lattice Flow Diverter was designated an “Innovative Medical Device” by the NMPA and fast-tracked for approval through the “Green Channel”. AccuMedical was recognized as a National High-Tech Enterprise in 2023 and selected as a National-level “Little Giant” Enterprise in 2024. Its innovation capabilities and clinical performance continue to earn industry-wide acclaim.
Deepening Collaboration to Shape the Future
During the expo, AccuMedical engaged in in-depth exchanges with numerous experts, scholars, and industry representatives, sharing its latest research and technological developments in neurointervention. Through active cooperation, the company continues to explore innovations aimed at providing a comprehensive portfolio of neurointervention solutions to physicians and patients worldwide. Its mission is to promote “real innovation for real application” in the localization of medical devices and address unmet clinical needs in cerebrovascular care.
Additionally, over 20 international students from Tsinghua University’s School of Public Policy and Management visited the Shunyi Exhibition Zone. They participated in cultural exchanges, scientific discussions, and project matchmaking with exhibitors like AccuMedical, opening new doors for global collaboration. A representative from AccuMedical stated that the company will continue increasing investment in R&D and launch more internationally competitive medical devices to provide higher-quality treatment options for patients worldwide and to contribute to the high-quality development of China’s medical device industry.
